A number of recent studies both in murine model systems and in hepatitis B virus (HBV)-infected patients indicate the importance of the immune response to the nucleocapsid antigens of the HBV in the induction and/or maintenance of chronic infection. Therefore, the purpose of this application is a detailed analysis of the immune responses to the particulate hepatitis B core antigen (HBcAg) and the secreted non- particulate form of the nucleocapsid, namely the HBeAg. This analysis will include: (1) establishing HBeAg-expressing transgenic (Tg) mice as a model of HBeAg/anti-HBe seroconversion in chronic HBV infection and a model in which to screen immunotherapeutic protocols; (2) use of novel immunoassays to examine serological and cellular responses to the nucleocapsid antigens in HBV-infected patients; (3) exploration of the importance of Th1 and Th2 cell subsets in the immune response to HBV nucleocapsid antigens and their possible role in chronicity; (4) analysis of the unique features of antigen presentation of the HBV nucleocapsid antigens to The cells and its possible role in chronicity; and (5) production of HBc/eAg-specific T cell receptor (TCR) transgenic mice and dual Tg mice expressing the HBc/eAgs as well as TCRs specific for these antigens. Although the specific aims represent basic and applied approaches, each project has been designed to answer questions relevant to chronic HBV infection. For example, does T cell tolerance play a role in chronic HBV infection? Do the enhanced humoral immune responses and relatively weak cellular responses observed in HBV chronic carriers reflect an imbalance in Th1 -Th2 cell subsets? If so, can the Th1 -Th2 imbalance be corrected in vivo? Does the enhanced immunogenicity of the HBcAg derive from entry into a specialized antigen presentation pathway? What effect does maternal anti-HBc have on the neonates HBcAg-specific The cell response? It is anticipated that the results of these studies will have diagnostic, therapeutic, and vaccine applications and will provide a better understanding of basic immune mechanisms responsible for viral persistence and clearance in chronic and acute HBV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI020720-16
Application #
6215560
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Johnson, Leslye D
Project Start
1984-05-01
Project End
2001-04-30
Budget Start
2000-01-01
Budget End
2000-04-30
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Immune Complex Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Lee, Byung O; Jones, Joyce E; Peters, Cory J et al. (2011) Identification of a unique double-negative regulatory T-cell population. Immunology 134:434-47
Nystrom, Jessica; Chen, Antony; Frelin, Lars et al. (2010) Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J Infect Dis 201:1867-79
Ameiss, Keith; Ashraf, Shamaila; Kong, Wei et al. (2010) Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine 28:6704-13
Frelin, Lars; Wahlstrom, Therese; Tucker, Amy E et al. (2009) A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 83:1379-92
Whitacre, David C; Lee, Byung O; Milich, David R (2009) Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 8:1565-73
Lee, Byung O; Tucker, Amy; Frelin, Lars et al. (2009) Interaction of the hepatitis B core antigen and the innate immune system. J Immunol 182:6670-81
Billaud, Jean-Noel; Peterson, Darrell; Lee, Byung O et al. (2007) Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 25:1593-606
Frelin, L; Brenndorfer, E D; Ahlen, G et al. (2006) The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease. Gut 55:1475-83
Billaud, Jean-Noel; Peterson, Darrell; Barr, Margaret et al. (2005) Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol 79:13656-66
Billaud, Jean-Noel; Peterson, Darrell; Schodel, Florian et al. (2005) Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J Virol 79:13641-55

Showing the most recent 10 out of 73 publications